Internal Medicine, Hematology & Oncology · Goldsboro, NC
NPI
1518304849
Since 2013
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
203 Cox Blvd
Goldsboro, NC, 27534
Phone (199) 580-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.9M
259,297 services
Medicare patients, 2024
1,268
Average age 75
Drug cost, 2024
$5.6M
1,558 prescriptions
Company payments, 2025
$2,078
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew M Sochat was code J1439 (injection, ferric carboxymaltose, 1 mg), 49,500 times for 57 patients. In total Matthew M Sochat billed 259,297 services in 159 codes, and Medicare paid $2.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 49,500 | 57 | $0.87 | $43K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 45,390 | 72 | $0.29 | $13K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 16,400 | 28 | $2.35 | $38K |
| J0897 Injection, denosumab, 1 mg | Office | 16,337 | 176 | $20.03 | $327K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 10,800 | 16 | $0.05 | $587 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,300 | 21 | $0.10 | $628 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 3,802 | 13 | $44.72 | $170K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,986 | 88 | $0.09 | $264 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,700 | 26 | $14.86 | $40K |
| 85025 Blood Count | Office | 2,147 | 776 | $7.53 | $16K |
| J3245 Injection, tildrakizumab, 1 mg | Office | 2,000 | 12 | $106.99 | $214K |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 1,520 | 15 | $0.06 | $97.43 |
| 36415 Venipuncture Blood Collection | Office | 1,451 | 781 | $7.83 | $11K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,330 | 61 | $0.69 | $924 |
| 80053 Clinical Chemistry | Office | 1,116 | 636 | $10.27 | $11K |
By year: 2022 $3.1M for 247,141 services; 2023 $3.3M for 210,507 services; 2024 $2.9M for 259,297 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,147 | 776 | $7.53 | $16K |
| 36415 Venipuncture Blood Collection | 1,451 | 781 | $7.83 | $11K |
| 80053 Clinical Chemistry | 1,116 | 636 | $10.27 | $11K |
| 82728 Clinical Chemistry | 381 | 252 | $13.22 | $5,037 |
| 83735 Clinical Chemistry | 236 | 102 | $6.52 | $1,538 |
| 83540 Clinical Chemistry | 190 | 151 | $6.27 | $1,192 |
| 83550 Clinical Chemistry | 190 | 152 | $8.48 | $1,611 |
| 81001 Clinical Chemistry | 91 | 47 | $3.11 | $283 |
| 85610 Clinical Chemistry | 83 | 14 | $4.20 | $349 |
Medicare prescription drug claims, 2024
In 2024, the drug Matthew M Sochat prescribed most often to Medicare patients was Letrozole, with 86 prescriptions and refills. In total Matthew M Sochat wrote 1,558 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 86 | 176 | 22 | $1,843 |
| Prolia Denosumab | 72 | 431 | 48 | $121K |
| Anastrozole Generic | 71 | 195 | 24 | $1,146 |
| Eliquis Apixaban | 65 | 81 | 22 | $46K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 63 | 63 | 19 | $2,621 |
| Ondansetron Hcl Generic | 53 | 53 | 35 | $865 |
| Oxycodone Hcl Generic | 44 | 44 | 17 | $1,153 |
| Brukinsa Zanubrutinib | 43 | 43 | Under 11 | $499K |
| Prednisone Generic | 41 | 72 | 22 | $224 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 39 | 39 | 11 | $3,211 |
| Xarelto Rivaroxaban | 37 | 53 | Under 11 | $30K |
| Verzenio Abemaciclib | 36 | 36 | Under 11 | $575K |
| Potassium Chloride Generic | 35 | 47 | 14 | $235 |
| Jakafi Ruxolitinib Phosphate | 30 | 30 | Under 11 | $525K |
| Alprazolam Generic | 26 | 26 | Under 11 | $70.24 |
Brand drugs: 665 claims; generic drugs: 893 claims; opioid claims: 199.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew M Sochat $2,078 ($2,078 in general payments such as food, travel and fees) from 28 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,164.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 15 | $1,164 |
| Merck Sharp & Dohme LLC MRK | 3 | $85.52 |
| Janssen Biotech, Inc. JNJ | 4 | $85.06 |
| Genentech USA, Inc. ROG.SW | 2 | $72.93 |
| Abbvie Inc. ABBV | 3 | $55.22 |
| GlaxoSmithKline, LLC. GSK | 3 | $54.73 |
| Taiho Oncology, Inc. 4578.T | 1 | $49.4 |
| Pfizer Inc. PFE | 3 | $49.24 |
| Daiichi Sankyo Inc. 4568.T | 2 | $37.61 |
| Celgene Corporation BMY | 2 | $36.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.